Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, today announced that two
abstracts with new data on the company’s novel innate cell engager
(ICE®) AFM24 have been accepted for poster presentation at the 37th
Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
The conference will take place on November 8-12, 2022, in Boston,
MA.
Poster presentation details
Poster number: 729
Title: Targeting Epidermal Growth Factor
Receptor (EGFR)-Expressing Solid Tumors with AFM24, a Novel CD16A
Bispecific Innate Cell Engager: Comprehensive Correlative Science
Findings from a Phase 1 Study
Authors: Gabriele Hintzen, Susanne Wingert,
Michael Emig, Pilar Nava-Parada, Kerstin Pietzko, Laura Kohlhas,
Uwe Reusch, Melissa M. Berrien‐Elliott, Todd A. Fehniger, Mark
Foster, Paolo Nuciforo, Ester Castillo Andreo, Sina Staeble,
Paulien Ravenstijn, Bettina Rehbein, Erich Rajkovic, Arndt
Schottelius, Joachim Koch
Date, time and location:
The poster session will take place on Thursday, November 10,
2022, from 9:00 a.m. to 9:00 p.m. EST, in the Boston Convention
& Exhibition Center, Poster Hall C. Required hours are 11:40
a.m. - 1:10 p.m. and 7:30 p.m. - 9:00 p.m. (poster reception).
Poster number: 746
Title: AFM24 and Atezolizumab
Combination in Patients with Advanced Epidermal Growth Factor
Receptor-expressing (EGFR+) Solid Tumors: Initial Results from the
Phase 1 Dose-escalation Study
Authors: Omar Saavedra, Daniela
Morales-Espinosa, Juanita Lopez, Eric Christenson, Anthony
El-Khoueiry, Andrés Cervantes, Christa Raab, Ulrike Gärtner,
Kerstin Pietzko, Laura Kohlhas, Daniel Schütz, Gabriele Hintzen,
Paulien Ravenstijn, Michael Emig, Pilar Nava-Parada
Date, time and location:
The poster will be shown on Friday, November 11, 2022, from 9:00
a.m. to 8:30 p.m. EST, in the Boston Convention & Exhibition
Center, Poster Hall C. Required hours are: 11:55 a.m. - 1:25 p.m.
and 7:00 p.m. - 8:30 p.m. (poster reception).
Additional information:
More details about the SITC Annual Meeting program are available
at www.sitcancer.org. Full abstracts will be made public on
November 7, 2022, 8:00 a.m. EST. In addition, e-posters will be
available on the SITC 2022's Virtual ePoster Hall to attendees.
About AFM24
AFM24 is a tetravalent, bispecific innate cell engager (ICE®)
that activates the innate immune system by binding to CD16A on
innate immune cells and EGFR, a protein widely expressed on solid
tumors, to kill cancer cells. Generated by Affimed’s
fit-for-purpose ROCK® platform, AFM24 represents a distinctive
mechanism of action that uses EGFR as a docking site to engage
innate immune cells for tumor cell killing through
antibody-dependent cellular cytotoxicity and antibody-dependent
cellular phagocytosis.
Affimed is evaluating AFM24 as monotherapy and in combinations
with other cancer treatments in patients with advanced
EGFR-expressing solid malignancies whose disease has progressed
after treatment with previous anticancer therapies.
AFM24-101, a monotherapy, first-in-human phase 1/2a open-label,
is a non-randomized, multi-center, multiple ascending dose
escalation and expansion study. Additional details may be found at
www.clinicaltrials.gov using the identifier NCT04259450.
AFM24 is also being evaluated in a phase 1/2a study in
combination with Roche’s PD-L1 checkpoint inhibitor atezolizumab
(AFM24-102, NCT05109442).
Furthermore, Affimed and NKGen Biotech initiated a phase 1/2a
study (AFM24-103), investigating AFM24 in combination with NKGen
Biotech’s NK cell SNK01 (NCT05099549).
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com Tel.: +1 (484)
888-8195
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024